Lopez LR, Ahn J-H, Alves T, Arthur JC. Microenvironmental factors that shape bacterial metabolites in inflammatory bowel disease. Front Cell Infect Microbiol. 2022 Jul 15;12:934619. doi: 10.3389/fcimb.2022.934619
Davis AE, Brogan AJ, Goodwin B, Nocea G, Lozano V. Short-term cost and efficiency analysis of raltegravir versus atazanavir/ritonavir or darunavir/ritonavir for treatment-naive adults with HIV-1 infection in Spain. HIV Clin Trials. 2017 Nov;18(5-6):214-22. doi: 10.1080/15284336.2017.1402144
Kim D, Lauria DT, Poulos C, Dong B, Whittington D. Effect of travel distance on household demand for typhoid vaccines: implications for planning. Int J Health Plann Manage. 2013 Mar 12;Advance Online.
Brogan AJ, Mrus J, Hill A, Sawyer AW, Smets E. Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States. HIV Clin Trials. 2010 May;11(3):133-44.
Manga N, Duffy JC, Rowe PH, Cronin MTD. Structure-based methods for the prediction of the dominant P450 enzyme in human drug biotransformation: consideration of CYP3A4, CYP2C9, CYP2D6. SAR QSAR Environ Res. 2005 Feb;16(1-2):43-61.
Bradley RH, National Institute of Child Health and Human Development (NICHD) Early Child Care Research Network, McLeod LD. Child care and common communicable illnesses in children aged 37 to 54 months. Arch Pediatr Adolesc. 2003 Feb;157(2):196-200. doi: 10.1001/archpedi.157.2.196
Cronin MT, Dearden JC, Duffy JC, Edwards R, Manga N, Worth AP, Worgan AD. The importance of hydrophobicity and electrophilicity descriptors in mechanistically-based QSARs for toxicological endpoints. SAR QSAR Environ Res. 2002 Mar;13(1):167-76.